Geltex Pharmaceuticals, Inc.

Lucent Technologies Inc.

At&t Bell Laboratories

Genzyme Corporation

Harvard College

Harvard Corporation

Thomas X Neenan

W Harry Mandeville, Iii

Stephen Randall Holmes-Farley

George M Whitesides

Francis Michael Houlihan

Richard Fitzpatrick

John S Petersen

Chad Cori Huval

Elsa Reichmanis

Venkata R Garigapati

Caroline Isabelle Bacon Kurtz

Mary Ellen Galvin-Donoghue

Edwin Arthur Chandross

Pradeep K Dhal

Omkaram Nalamasu

Sanjay Patel

Janet Mihoko Kometani

Caroline Kurtz

Jeffrey D Klinger

Philip J Goddard

A method for treating a microbial infection in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising an amino group or an ammonium group attached to the polymer backbone via an aliphatic spacer group. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.

Ionic polymers as anti-infective agents

A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.

Ionic polymers as toxin-binding agents

A photorecording medium contains a polymeric matrix, typically cross-linked to provide a desired level of physical stability, and a photoimageable system containing a photoactive monomer. Unlike previous polymer media, which tend to contain a substantially homogeneous dispersion of photoimageable system and matrix polymer, the matrix and photoimageable system of the invention are phase separated, yet still exhibit low light scattering such that useful holographic properties are possible.

Photorecording medium, process for fabricating medium, and process for holography using medium

The invention relates to the unexpected discovery that bismuth-containing compounds are effective in the treatment of oral mucositis in a mammal. Thus, the invention relates, in one aspect to a method of treating oral mucositis comprising administering an effective amount of a pharmaceutically acceptable bismuth-containing compound, such as a bismuth salt or bismuth complex. In a preferred embodiment, the bismuth compound is an organic or inorganic salt such as, bismuth subsalicylate, bismuth subgallate, bismuth aluminate, bismuth citrate, bismuth subcitrate, bismuth carbonate, bismuth subcarbonate, tripotassium dicitrato bismuthate, bismuth nitrate, bismuth subnitrate, bismuth tartrate and mixtures thereof, preferably, bismuth subsalicylate and bismuth subgallate.

Bismuth compounds for the treatment and prevention of mucositis

The present invention relates to antimicrobial compositions including pharmaceutical compositions and treatment regimens for preventing or treating a microbial infection in a mammal, such as a human, by administering to the mammal, a therapeutically effective amount of a polymer and a therapeutically effective amount of an antibacterial agent.

Antimicrobial compositions and methods

The present invention relates to a method of treating a viral infection in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer comprising a plurality of pendant hydrophobic groups and a plurality of pendant acid functional groups. The acid functional groups are connected directly to the polymer backbone or via an aliphatic spacer group of 1 to about 20 atoms in length.

Antiviral polymers comprising acid functional groups and hydrophobic groups

The present invention includes polymerizable monomers comprising a fucoside moiety. In one embodiment, the monomer has a polymerizable functional group, such as an olefinic bond, to which the fucoside moiety is attached by a spacer group, for example, an alkylene group, or an alkylene group wherein one or more carbon atoms are substituted by heteroatoms, such as oxygen, nitrogen or sulfur atoms. The present invention also includes polymers comprising one or more fucoside moieties, such as pendant fucoside moieties, which can inhibit or prevent rotavirus infection in a mammal. Such a polymer can comprise, for example, a monomer of the present invention. The polymer can be a homopolymer or a copolymer, and can have, for example, a polyacrylamide, polyacrylate or polystyrene backbone. In another embodiment, the present invention comprises a method for treating a rotavirus infection in a mammal, for example, a human, by administering to the mammal a therapeutically effective amount of a polymer comprising one or more glycoside moieties, such as pendant glycoside moieties. The glycoside moieties can be, for example, fucoside moieties or sialic acid moieties. The polymer can be a homopolyrner or a co-polymer. In one embodiment, the polymer is a copolymer comprising a glycoside-bearing monomer and a hydrophobic monomer. In another embodiment, the polymer to be administered comprises two or more different glycoside-bearing monomers.

Polyvalent polymers for the treatment of rotavirus infection

Antiviral polymers comprising acid functional groups and hydrophobic

Ionic polymers as toxin binding agents

A process for device fabrication is disclosed. In the process, an energy sensitive material is formed on a substrate. The energy sensitive resist material contains a polymer or a polymer blend in combination with an energy-sensitive material such as a photoacid generator. At least three substituents are distributed on the polymer blend. The first of these substituents is a hydroxyl (OH) group. The second of these substituents is an acid-sensitive or acid labile group which is cleaved in the presence of acid and replaced by an OH group. The third of these substituents forms hydrogen bonds with the first group. The ratio of the number of OH substituents relative to the number of substituents that hydrogen bond to the OH substituents (mole percent) is about 40:1 to at least about 1:1. The relative amounts of the first and third substituents is selected to provide a resist material with a glass transition temperature of at least about 60.degree.. After a layer of the energy sensitive resist material is formed on the substrate, an image of a pattern is introduced into the energy-sensitive material via a patternwise exposure to radiation. The image is thereafter developed into a pattern, and transferred into the underlying substrate.

Lithographic process and energy-sensitive material for use therein

The present invention relates to a method for removing bile salts from a patient, comprising the step of administering to the patient a therapeutically effective amount of a polymer network composition comprising a cationic polymer. In one embodiment, the polymer network is an interpenetrating polymer network. In another embodiment, the polymer network is a semi-interpenetrating polymer network.

Interpenetrating polymer networks for sequestration of bile acids

Growing community of inventors

Boston, MA, United States of America

Thomas X Neenan